Clinical Research Coordinator

NIDA SHOAIB 713-***-****

CURRICULUM VITAE **************@*****.***

CURRICULUM VITAE

EDUCATION:

**** – 2013 MD

Bachelors of Medicine & Bachelor of Surgery (M.B.B.S)

Liaquat College of Medicine & Dentistry

Darul Sehat Hospital,

Karachi, Pakistan

CERTIFICATIONS:

CITI GCP Certificate

IATA CERTIFICATE

NIH Certificate

CLINICAL EXPERIENCE:

2020 – Present Clinical Research Coordinator – DM Clinical Research

2019 – 2020 Research Assistant & Independent Joint Assessor – DM Clinical Research

2019 Cardiovascular Associates of North Houston – Internship

2016 - 2019 Medical Assistant - Shifa Healthcare & Community Services

2013 – 2015 MD – Jinnah Post Graduate & Medical Center

RESEARCH & COORDINATING EXPERIENCE:

Protocol M13-542: A Phase 3, Randomized, Double- Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects and Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDS (bDMARDs)

Protocol M14-465: A Phase 3, Randomized, Double- Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)

Protocol M15-998: A Phase 3, Randomized, Double- Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who have a history of Inadequate response or intolerance to Biological Therapy(ies) (KEEPsAKE 2)

Protocol CL04041024 Credo 4: A Multicenter, Open-Label, Phase III Study of the efficacy and safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis.

Protocol 201791 Contrast 2: A 52-week, Phase III, multicenter, randomized, double-blind, efficacy and safety study, comparing GSK3196165 with Placebo and with Tofacitinb in combination with conventional synthetic DMARDs, in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to conventional synthetic DMARDs or biologic DMARDs

Protocol 202018 Contrast 3: A 24-week, phase 3, multicenter, randomized, double-blind, efficacy and safetystudy, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors

14V-MC-JAJA RA BRIDGE: A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis.

14V-MC-JAJA RA BRANCH: A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis

Protocol 201791 Contrast X: A Multi-center long-term extension study to assess the safety and efficacy of GSK3196165 in the treatment of rheumatoid arthritis.

Protocol M20-466: A Randomized, Double-blind, placebo- controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with Moderately to Severely active Rheumatoid arthritis with inadequate response to biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs)(Pro00053783)

Protocol mRNA(Moderna)-1273-P301: A Phase 3, Randomized, Stratified, Observer-Blind,

Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older.

Protocol COVID19-311: Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine against COVID-19 Disease, administered Intradermally followed by flectroporation in Healthy Adults at High Risk of SARS-CoV-2 Exposure.

PROTOCOL NO. 2019nCoV-101: A 2-part, Phase 1/2, randomized, observer-blinded study to evaluate the safety and immunogenicity of a sars-cov-2 recombinant spike protein nanoparticle vaccine (Sars-CoV-2 RS) with or without matrix-mtm adjuvant in healthy subjects

PROTOCOL Pfizer Covid: A phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of sars-cov-2 RNA vaccine candidates against covid-19 in healthy individuals

Contact this candidate